Catalyst Dossier · compiled by CeliA 🧫
Lakewood-Amedex Biotherapeutics Inc. (LABT)
Pharmaceutical Preparations · market cap $10M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Lakewood-Amedex Biotherapeutics Inc. (LABT) is a micro-cap pharmaceutical company with 5 employees and a market cap of approximately $14 million, trading near $1.93 per share. Its sole disclosed pipeline asset is Bisphosphocin Nu-3, a compound of undisclosed mechanism currently in Phase 2 development for Diabetic Foot Infections. The company reports essentially zero cash on hand and a runway of approximately 0.1 months, representing an acute existential financing risk.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Bisphosphocin Nu-3 | Phase 2 | Diabetic Foot Infections |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$1.50–$8.65
vs 50-day MA
—
vs 200-day MA
—
Realized vol
342.4%
Max drawdown
-82.7%
Daily closes through 2026-05-15. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LABT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.